Merck third-quarter profit beats estimate, but Januvia sales slump

(Reuters) - Merck & Co Inc reported better-than-expected third-quarter earnings, helped by cost cutting, but sales of its Januvia diabetes treatment fell, raising more concerns about growth prospects for the company's biggest product.

from Reuters: Business News http://feeds.reuters.com/~r/reuters/businessNews/~3/SsHpXJEOj-U/story01.htm